You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. DEVELOPMENT OF A BIOLOGICALLY-ACTIVE VASCULAR GRAFT

    SBC: BIOMOD SURFACES            Topic: N/A

    Medium (6-8mm) and small (

    STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
  2. NANOFIBER TECHNOLOGY IN SMALL-DIAMETER VASCULAR GRAFTS

    SBC: BIOMOD SURFACES            Topic: N/A

    There is no small-diameter vascular prosthesis that is capable of emulating the biologic and physical properties of the normal arterial wall. The goal of this proposal is to develop a small-diameter prosthetic vascular graft using nanofiber technology. Our hypothesis is creating a nanofibrous vascular graft by electrospinning an ionic polyurethane will result in a graft that possesses properties s ...

    STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
  3. DEVELOPMENT OF A MIDDLE EAR BALLOON IMPLANT

    SBC: BOSTON MEDICAL PRODUCTS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Development of a new type of middle ear implant, a "middle ear balloon" is proposed. This implant is intended to restore hearing in non-aerated ears by creating and permanently maintaining an air or gas-filled space within the middle ear. Non-aerated middle ears resulting from eustachian tube dysfunction camonly occur in chronic otitis media (COM) and in otitis ...

    STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
  4. IDENTIFICATION AND EXPRESSION OF INSECTICIDE TARGETS

    SBC: CAMBRIA BIOSCIENCES, LLC            Topic: N/A

    DESCRIPTION (Provided by applicant): Insect-borne infectious diseases such as malaria affect at least 1 billion people worldwide, and over 1.5 million of these infected individuals die each year. Malarial parasites and many other vector-borne pathogens have developed resistance to current drugs, and vaccines are not available or feasible for many of these pathogens. Insect vector control programs ...

    STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
  5. ORAL THERAPEUTIC FOR INDUCING FETAL HEMOGLOBIN

    SBC: Gene Regulation Laboratories            Topic: N/A

    DESCRIPTION (provided by applicant): Sickle cell disease (SCD) and beta-thalassemia are genetic disorders caused by molecular mutations affecting the genes for adult hemoglobin. With a world-wide birth prevalence of 2/1,000, hemoglobin disorders are the most common genetic diseases in the world (360,000 patients/year - 250,000 with sickling disorders and 110,000 with thalassemias. These conditions ...

    STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
  6. ORAL THERAPEUTICS FOR VIRAL MALIGNANCIES

    SBC: Gene Regulation Laboratories            Topic: N/A

    DESCRIPTION (provided by applicant): Epstein-Barr virus (EBV) is associated with a number of human lymphoid malignancies and carcinomas for which there are presently few effective treatments. Each year in the U.S., there are approximately 27,000 people afflicted with diseases caused by the Epstein-Barr virus, and an additional 107,000 people afflicted with malignancies associated with the Epstein ...

    STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
  7. GRADIENT COILS TO ENHANCE MRI RESEARCH IN MENTAL HEALTH

    SBC: INSIGHT NEUROIMAGING SYSTEMS, LLC            Topic: N/A

    LONG RANGE OBJECTIVES To develop products that enhance research methods and applications in animal research using magnetic resonance imaging to study mental illness. PHASE I The planar gradient coil, or PROTOTYPE we propose to develop will optimize the working area inside MR spectrometers expanding the experimental applications and the types of animals that can be studied in small bore ultra-high ...

    STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
  8. DEVELOPMENT OF STANDARDIZED MILK THISTLE PRODUCT

    SBC: NATURAL PHARMACIA INTERNATIONAL, INC.            Topic: N/A

    DESCRIPTION (Provided by applicant): The objective of this Phase I and II fast track application is to develop a standardized milk thistle product and to assure a quality controlled and reliable source for future basic and clinical studies. Natural Pharmacia International, Inc, an established natural products laboratory, has established an excellent consortial team to establish a standardized milk ...

    STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
  9. VISIBABBLE, A SYSTEM FOR EARLY SPEECH INTERVENTION

    SBC: Speech Technology and Applied Research Corporation            Topic: N/A

    This project will develop sound recognition software to provide real-time visual reinforcement of vocalizations produced by infants or preschool children. This program is intended for children who are delayed in the frequency and variety of pre-speech vocalizations they produce and, hence, are at risk for being non-speaking. This will provide an automated training system to maintain and develop ch ...

    STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
  10. Development of small near-infrared laser system capable of improving immune respo

    SBC: SEMINEX CORPORATION            Topic: NIAID

    DESCRIPTION (provided by applicant): The broad and long-term objective of this project is to amplify the effectiveness of vaccines without the use of chemical or biological adjuvants. We will address this objective by demonstrating the feasibility for small laser- based devices to enhance responses to intradermal vaccination. A number of investigators have shown that a promising new way to make va ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government